FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384493002> ?p ?o ?g. }

• W4384493002 abstract "Abstract The presence of hepatitis B virus (HBV) covalently closed circular (ccc) DNA (cccDNA), which serves as a template for viral replication and integration of HBV DNA into the host cell genome, sustains liver pathogenesis and constitutes an intractable barrier to the eradication of chronic HBV infection. The current antiviral therapy for HBV infection, using nucleos(t)ide analogues (NAs), can suppress HBV replication but cannot eliminate integrated HBV DNA and episomal cccDNA. Clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 is a powerful genetic tool that can edit integrated HBV DNA and minichromosomal cccDNA for gene therapy, but its expression and delivery require a viral vector, which poses safety concerns for therapeutic applications in humans. In the present study, we used synthetic guide RNA (gRNA)/Cas9‐ribonucleoprotein (RNP) as a nonviral formulation to develop a novel CRISPR/Cas9‐mediated gene therapy for eradicating HBV infection. We designed a series of gRNAs targeting multiple specific HBV genes and tested their antiviral efficacy and cytotoxicity in different HBV cellular models. Transfection of stably HBV‐infected human hepatoma cell line HepG2.2.15 with HBV‐specific gRNA/Cas9 RNPs resulted in a substantial reduction in HBV transcripts. Specifically, gRNA5 and/or gRNA9 RNPs significantly reduced HBV cccDNA, total HBV DNA, pregenomic RNA, and HBV antigen (HBsAg, HBeAg) levels. T7 endonuclease 1 (T7E1) cleavage assay and DNA sequencing confirmed specific HBV gene cleavage and mutations at or around the gRNA target sites. Notably, this gene‐editing system did not alter cellular viability or proliferation in the treated cells. Because of their rapid DNA cleavage capability, low off‐target effects, low risk of insertional mutagenesis, and readiness for use in clinical application, these results suggest that synthetic gRNA/Cas9 RNP‐based gene‐editing can be utilized as a promising therapeutic drug for eradicating chronic HBV infection." @default.
• W4384493002 created "2023-07-18" @default.
• W4384493002 creator A5001140173 @default.
• W4384493002 creator A5015282600 @default.
• W4384493002 creator A5019117193 @default.
• W4384493002 creator A5027015541 @default.
• W4384493002 creator A5036266692 @default.
• W4384493002 creator A5044544424 @default.
• W4384493002 creator A5045284378 @default.
• W4384493002 creator A5045625749 @default.
• W4384493002 creator A5048888623 @default.
• W4384493002 creator A5050487837 @default.
• W4384493002 creator A5056143043 @default.
• W4384493002 creator A5059365171 @default.
• W4384493002 creator A5061643459 @default.
• W4384493002 creator A5066071426 @default.
• W4384493002 creator A5072422702 @default.
• W4384493002 creator A5073594714 @default.
• W4384493002 date "2023-07-01" @default.
• W4384493002 modified "2023-10-17" @default.
• W4384493002 title "Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication" @default.
• W4384493002 cites W1797768250 @default.
• W4384493002 cites W1799522345 @default.
• W4384493002 cites W1844576826 @default.
• W4384493002 cites W1978314081 @default.
• W4384493002 cites W2010338556 @default.
• W4384493002 cites W2023422990 @default.
• W4384493002 cites W2031579836 @default.
• W4384493002 cites W2040195110 @default.
• W4384493002 cites W2042396550 @default.
• W4384493002 cites W2064364170 @default.
• W4384493002 cites W2067119305 @default.
• W4384493002 cites W2076038974 @default.
• W4384493002 cites W2088474579 @default.
• W4384493002 cites W2088572513 @default.
• W4384493002 cites W2113446817 @default.
• W4384493002 cites W2120426460 @default.
• W4384493002 cites W2136833091 @default.
• W4384493002 cites W2141860194 @default.
• W4384493002 cites W2147456300 @default.
• W4384493002 cites W2150690792 @default.
• W4384493002 cites W2164383394 @default.
• W4384493002 cites W2170264372 @default.
• W4384493002 cites W2274986902 @default.
• W4384493002 cites W2381743533 @default.
• W4384493002 cites W2395331476 @default.
• W4384493002 cites W2403531472 @default.
• W4384493002 cites W2512452943 @default.
• W4384493002 cites W2545689480 @default.
• W4384493002 cites W2582215039 @default.
• W4384493002 cites W2599402605 @default.
• W4384493002 cites W2605770782 @default.
• W4384493002 cites W2611134270 @default.
• W4384493002 cites W2611446801 @default.
• W4384493002 cites W2625448726 @default.
• W4384493002 cites W2778928474 @default.
• W4384493002 cites W2818540548 @default.
• W4384493002 cites W2914866839 @default.
• W4384493002 cites W2955654823 @default.
• W4384493002 cites W2965273685 @default.
• W4384493002 cites W2967770094 @default.
• W4384493002 cites W2972907673 @default.
• W4384493002 cites W2982938168 @default.
• W4384493002 cites W2992036306 @default.
• W4384493002 cites W3006880239 @default.
• W4384493002 cites W3009519335 @default.
• W4384493002 cites W3097071384 @default.
• W4384493002 cites W4224948644 @default.
• W4384493002 cites W4226124630 @default.
• W4384493002 cites W4234464746 @default.
• W4384493002 cites W4293728526 @default.
• W4384493002 cites W576512939 @default.
• W4384493002 cites W577533421 @default.
• W4384493002 doi "https://doi.org/10.1002/jmv.28952" @default.
• W4384493002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37455550" @default.
• W4384493002 hasPublicationYear "2023" @default.
• W4384493002 type Work @default.
• W4384493002 citedByCount "0" @default.
• W4384493002 crossrefType "journal-article" @default.
• W4384493002 hasAuthorship W4384493002A5001140173 @default.
• W4384493002 hasAuthorship W4384493002A5015282600 @default.
• W4384493002 hasAuthorship W4384493002A5019117193 @default.
• W4384493002 hasAuthorship W4384493002A5027015541 @default.
• W4384493002 hasAuthorship W4384493002A5036266692 @default.
• W4384493002 hasAuthorship W4384493002A5044544424 @default.
• W4384493002 hasAuthorship W4384493002A5045284378 @default.
• W4384493002 hasAuthorship W4384493002A5045625749 @default.
• W4384493002 hasAuthorship W4384493002A5048888623 @default.
• W4384493002 hasAuthorship W4384493002A5050487837 @default.
• W4384493002 hasAuthorship W4384493002A5056143043 @default.
• W4384493002 hasAuthorship W4384493002A5059365171 @default.
• W4384493002 hasAuthorship W4384493002A5061643459 @default.
• W4384493002 hasAuthorship W4384493002A5066071426 @default.
• W4384493002 hasAuthorship W4384493002A5072422702 @default.
• W4384493002 hasAuthorship W4384493002A5073594714 @default.
• W4384493002 hasConcept C104317684 @default.
• W4384493002 hasConcept C132455925 @default.
• W4384493002 hasConcept C140704245 @default.
• W4384493002 hasConcept C153911025 @default.
• W4384493002 hasConcept C159047783 @default.

• next